Novartis CEO Vas Narasimhan Talks Psoriasis Drug, China Growth, M&A
Bloomberg Talks
00:00
Intro
This chapter explores Novartis' financial performance and strategic investments amidst potential pharmaceutical tariffs. The focus is on the company's $23 billion plan to bolster domestic manufacturing and lessen dependency on foreign production.
Transcript
Play full episode
